IOL Chemicals and Pharmaceuticals Ltd

This approval authorizes the company to export Ibuprofen to the Chinese markets. Ibuprofen is a widely used non-steroidal anti-inflammatory drug (NSAID) effective in relieving pain, reducing inflammation, and lowering fever. IOL Chemicals & Pharmaceuticals is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP has a wide presence across major therapeutic categories like pain management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets. The company's consolidated net profit declined 11% to Rs 20.53 crore in Q3 FY25 as compared with Rs 23.08 crore in Q3 FY24. Net sales increased 0.6% YoY to Rs 523.30 crore in Q3 FY25. The scrip declined 1.01% to settle at Rs 65.42 on the BSE.Powered by Capital Market - Live

The said certification will enable the company to export Quetiapine Fumarate to European and other countries that accept CEPs. Quetiapine Fumarate is an antipsychotic drug which is widely used to treat various mental health disorders. IOL Chemicals and Pharmaceuticals is a pharma API and speciality chemicals manufacturer. The company's consolidated net profit declined 11% to Rs 20.53 crore in Q3 FY25 as compared with Rs 23.08 crore in Q3 FY24. Net sales increased marginally to Rs 523.30 crore in Q3 FY25, up .0.6% as compared with Rs 520.39 crore in Q3 FY24.Powered by Capital Market - Live

IOL Chemicals & Pharmaceuticals has fixed 18 February 2025 as record date for interim dividend of Rs 4 per share for FY 2024-25. Powered by Capital Market - Live

IOL Chemicals & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 12 February 2025, inter alia, have recommended the interim dividend of Rs 4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of IOL Chemicals & Pharmaceuticals declined 11.05% to Rs 20.53 crore in the quarter ended December 2024 as against Rs 23.08 crore during the previous quarter ended December 2023. Sales rose 0.56% to Rs 523.30 crore in the quarter ended December 2024 as against Rs 520.39 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales523.30520.39 1 OPM %8.968.52 - PBDT46.4848.43 -4 PBT27.8032.09 -13 NP20.5323.08 -11 Powered by Capital Market - Live

IOL Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live

Accordingly, the face value of each share of the company will change to Rs 2, which is one-fifth of its present face value of Rs 10. The company expects to complete the stock split proposal within a period of two months from the date of shareholder's approval. Offering rationale for the stock split proposal, IOL Chemicals said: 'The split of equity shares will make the shares more affordable, thereby increasing its attractiveness to a wider range of investors. This move is expected to potentially boost investor participation and improve liquidity in the market.' IOL Chemicals and Pharmaceuticals is a pharma API and speciality chemicals manufacturer. The company's consolidated net profit declined 49.4% to Rs 19.15 crore on 3.6% increase in net sales to Rs 525.75 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

IOL Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 27 December 2024.Powered by Capital Market - Live

The company will consider and approve the alteration in the share capital of the company by sub-division / split of existing equity shares having face value of Rs 10 each, fully paid up, as may be determined by the board of directors. IOL Chemicals and Pharmaceuticals is a pharma API and speciality chemicals manufacturer. Its consolidated net profit declined 49.4% to Rs 19.15 crore on 3.6% increase in net sales to Rs 525.75 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

The Board of IOL Chemicals & Pharmaceuticals will meet on 27 December 2024 to consider and approve the alteration in the share capital of the Company by sub-division / split of existing equity shares having face value of Rs. 10 each. Powered by Capital Market - Live